NCT01284166View on ClinicalTrials.gov

Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution

1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.